Research programme: acetylcholinesterase - Protalix Biotherapeutics

Drug Profile

Research programme: acetylcholinesterase - Protalix Biotherapeutics

Alternative Names: AChE programme - Protalix Biotherapeutics

Latest Information Update: 12 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boyce Thompson Institute for Plant Research; Hebrew University of Jerusalem
  • Developer Protalix Biotherapeutics
  • Class Antitoxins; Recombinant proteins
  • Mechanism of Action Cholinesterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Poisoning

Most Recent Events

  • 07 Mar 2012 No development reported - Preclinical for Poisoning in Israel (Parenteral)
  • 22 Jan 2008 Protalix Biotherapeutics extends its research agreement with Yissum Research Development Company to include a collaborative research programme at the Hebrew University of Jerusalem
  • 22 Jan 2008 Preclinical trials in Poisoning in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top